DAXOR CORP (DXR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US2394671034
DAXOR CORP financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.13 m USD | 503,424.00 USD |
| Gross profit | 2.13 m USD | 188,741.00 USD |
| Operating income | 621,423.00 USD | 9.19 m USD |
| Net income | 536,334.00 USD | 9.17 m USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About DAXOR CORP
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
More stocks
- McKinley Acquisition Corp (MKLY)
- Yorkville Acquisition Corp. (MCGA)
- Digital Asset Acquisition Corp. (DAAQ)
- vTv Therapeutics Inc. (VTVT)
- Plum Acquisition Corp, IV (PLMK)
- MARCHEX INC (MCHX)
- BIMINI CAPITAL MANAGEMENT, INC. (BMNM)
- FARADAY FUTURE INTELLIGENT ELECTRIC INC. (FFAI)
- ALL THINGS MOBILE ANALYTIC, INC. (ATMH)
- GREIF, INC (GEF-B)
- BEL FUSE INC /NJ (BELFB)
- Biglari Holdings Inc. (BH)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.